Therapeutic Potential of Tyrosine Kinase Inhibitors in Breast Cancer

References

• Parkin D.M., Bray F.I., Devesa S.S. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 2001; 37(Suppl. 8)S4–S66
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts and figures 2002. http://www.cancer.org 2002.
   Google Scholar
• Ries L.A.G., Eisner M.P., Kosary C.L., Hankey B.F., Miller B.A., Clegg L., Edwards B.K. SEER Cancer Statistics Review. National Cancer Institute, Bethesda, MD 2001
   Google Scholar
• Fentiman I.S. The dilemma of in situ carcinoma of the breast. Int. J. Clin. Pract. 2001; 55: 680–683
   PubMed Web of Science ®Google Scholar
• Fisher B., Land S., Mamounas E., Dignam J., Fisher E.R., Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin. Oncol. 2001; 28: 400–418
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN) Guidelines. www.nccn.org 2000.
   Google Scholar
• PDQ Guidelines. www.cancer.gov 2002.
   Google Scholar
• Fisher B., Dignam J., Wolmark N., Wickerham D.L., Fisher E.R., Mamounas E., Smith R., Begovic M., Dimitrov N.V., Margolese R.G., Kardinal C.G., Kavanah M.T., Fehrenbacher L., Oishi R.H. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353: 1993–2000
   PubMed Web of Science ®Google Scholar
• Salvini P., Ripa C., Ginanni V. Metastatic breast cancer: what are the objectives?. Tumori 2000; 86: S22–S28
   PubMedGoogle Scholar
• DiAugustine R.P., Richards R.G., Sebastian J. EGF-related peptides and their receptors in mammary gland development. J. Mammary Gland Biol. Neoplasia 1997; 2: 109–117
   PubMed Web of Science ®Google Scholar
• Normanno N., Ciardiello F. EGF-related peptides in the pathophysiology of the mammary gland. J. Mammary Gland Biol. Neoplasia 1997; 2: 143–151
   PubMed Web of Science ®Google Scholar
• Walker R.A., Dearing S.J. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res. Treat. 1999; 53: 167–176
   PubMed Web of Science ®Google Scholar
• Klijn J.G., Berns P.M., Schmitz P.I., Foekens J.A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr. Rev. 1992; 13: 3–17
   PubMed Web of Science ®Google Scholar
• Klijn J.G., Look M.P., Portengen H., Alexieva-Figusch J., van Putten W.L., Foekens J.A. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res. Treat. 1994; 29: 73–83
   PubMed Web of Science ®Google Scholar
• Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–182
   PubMed Web of Science ®Google Scholar
• Wright C., Nicholson S., Angus B., Sainsbury J.R., Farndon J., Cairns J., Harris A.L., Horne C.H. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br. J. Cancer 1992; 65: 118–121
   PubMed Web of Science ®Google Scholar
• Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr. Relat. Cancer 2001; 8: 191–195
   PubMed Web of Science ®Google Scholar
• Sainsbury J.R., Farndon J.R., Needham G.K., Malcolm A.J., Harris A.L. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987; 1: 1398–1402
   PubMed Web of Science ®Google Scholar
• Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001; 344: 783–792
   PubMed Web of Science ®Google Scholar
• Saltz L., Rubin M.S., Hochster H.S., Tchekmeydian N.S., Waksal H.W., Needle M.N., Lobuglio A.F. Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11-refractory colorectal cancer that express epidermal growth factor receptor. Clin. Cancer Res. 2001; 7(Suppl.), (abs 559)
   PubMedGoogle Scholar
• Abbruzzese J.L., Rosenberg A.H., Lobuglio A.F., Schmidt W.G., Xiong Q., Wolff R.A., Waksal H.W., Needle M.N. Promising survival results in a phase II study of cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Clin. Cancer Res. 2001; 7(Suppl.), (abs 534)
   Google Scholar
• Hong W.K., Arquette M., Nabel L., Needle M.N., Waksal H.W., Herbst R.S. Efficacy and safety of the anti-epidermal growth factor antibody IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck refractory to cisplatin containing chemotherapy. Proc. Am. Soc. Clin. Oncol. 2001; 20: 224a, (abs 895)
   Google Scholar
• Figlin R.A., Belldegrun A., Lohner M.E., Roskos L., Yang X.-D., Schwab G., Weiner L.M. ABX-EGF: a fully human anti-EGF receptor antibody in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 2001; 20: 276a, (abs 1102)
   Google Scholar
• Pfister D.G., Lipton A., Belt R., Motzer R.J., Winston C., Metz E.M., Sherman E.J., Curnow R.T. A phase I trial of the epidermal growth factor receptor (EGFR)-directed bispecific antibody MDX-447 in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 1999; 18: 433a, (abs 1667)
   Google Scholar
• Crombet-Ramos T., Torres L., Solano M.E., Cruz T., Osorio M., Renginfo E., Catala M., Neninger E., Perera A., Torres O., Perez R., Lage A. Pharmacological and clinical evaluation of the humanized anti-EGFR monoclonal antibody h-R3 in patients with advanced epithelial carcinomas. Proc. Am. Soc. Clin. Oncol. 2001; 20: 254a, (abs 1012)
   Google Scholar
• Bier H., Hoffmann T., Hauser U., Wink M., Ochler M., Kovar A., Muser M., Knecht R. Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother. Pharmacol. 2001; 47: 519–524
   PubMed Web of Science ®Google Scholar
• Modjtahedi H., Hickish T., Nicolson M., Moore J., Styles J., Eccles S., Jackson E., Salter J., Sloane J., Spencer L., Priest K., Smith I., Dean C., Gore M. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br. J. Cancer 1996; 73: 228–235
   PubMed Web of Science ®Google Scholar
• Baselga J., Yano S., Giaccone G., Nakagawa K., Tamura T., Douillard J., Nishiwaki Y., Vansteenkiste J., Kudou S., Rischin D., Eek R.W., Averbuch S., Macleod A., Feyereislova A., Dong R.-P., Fukuoka M. Initial results from a phase II trial of ZD1839 (‘Iressa’) as second- and third-line monotherapy for patients with advanced non-small-cell lung cancer (IDEAL 1). Clin. Cancer Res. 2001; 7(Suppl.), (abs 630A)
   PubMedGoogle Scholar
• Perez-Soler R., Chachoua A., Huberman M., Karp D., Rigas J., Hammond L., Rowinsky E., Preston G., Ferrante K.J., Allen L.F., Nadler P.I., Bonomi P. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advanced EGFR-expressing, non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 2001; 20: 310a, (abs 1235)
   Google Scholar
• Senzer N., Soulieres D., Siu L., Agarwala S., Vokes E., Hidalgo M., Silberman S., Allen L., Ferrante K., Fisher D., Marsolais C., Nadler P. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol. 2001; 20: 2a, (abs 6)
   Google Scholar
• Finkler N., Gordon A., Crozier M., Edwards R., Figueroa J., Garcia A., Hainsworth J., Irwin D., Bates A., Silberman S., Allen L., Ferrante K., Fisher D. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc. Am. Soc. Clin. Oncol. 2001; 20: 208a, (abs 831)
   Google Scholar
• Garrison M.A., Tolcher A., McCreery H., Rowinsky E.K., Schott A., Mace J., et al. A phase I and pharmacokinetic study of CI-1033, a pan-ErbB tyrosine kinase inhibitor, given orally on days 1, 8 and 15 every 28 days to patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 2001; 20, (abs 283)
   Google Scholar
• Shin D.M., Nemunaitis J., Zinner R.G., Donato N.J., Shin H.J.C., Myers J.N., Zhang P.S., Zentgraf R.E., Khuri F.R, Glisson B.S., Eiseman I., Olson S., Bycott P., Lenehan P.F., Hong W.K. A phase I clinical and biomarker study of CI-1033, a novel pan-erbB tyrosine kinase inhibitor in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 2001; 20: 82a, (abs 324)
   Google Scholar
• Papadimitrakopoulou V.A., Murren J.R., Fidler I.J., Bucana C.D., Sizer K., Cohen P., Ravera C., Abbruzzese J.L. A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166, a novel tyrosine kinase inhibitor, in patients with advanced cancers. Clin. Cancer Res. 2001; 7(Suppl.), (abs 276)
   PubMedGoogle Scholar
• Hoekstra R., Dumez H., Eskens F., Sizer K., Cohen P., Ravera C., Verweij J., Van Oosterom A. A phase I and pharmacological study of intermittent dosing of PKI166, a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally to patients with advanced cancer. Clin. Cancer Res. 2001; 7(Suppl.), (abs 585)
   Google Scholar
• Baselga J., Pfister D., Cooper M.R., Cohen R., Burtness B., Bos M., D'Andrea G., Seidman A., Norton L., Gunnett K., Falcey J., Anderson V., Waksal H., Mendelsohn J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 2000; 18: 904–914
   PubMed Web of Science ®Google Scholar
• Herbst R.S., Kim E.S., Harari P.M. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert. Opin. Biol. Ther. 2001; 1: 719–732
   PubMed Web of Science ®Google Scholar
• Yang X.D., Jia X.C., Corvalan J.R., Wang P., Davis C.G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol. 2001; 38: 17–23
   PubMed Web of Science ®Google Scholar
• Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., Wolter J.M., Paton V., Shak S., Lieberman G., Slamon D.J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 1999; 17: 2639–2648
   PubMed Web of Science ®Google Scholar
• Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002; 20: 719–726
   PubMed Web of Science ®Google Scholar
• Ciardiello F., Caputo R., Bianco R., Damiano V., Fontanini G., Cuccato S., De Placido S., Bianco A.R., Tortora G. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. 2001; 7: 1459–1465
   PubMed Web of Science ®Google Scholar
• Anderson N.G., Ahmad T., Chan K., Dobson R., Bundred N.J. ZD1839 (‘Iressa’), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int. J. Cancer 2001; 94: 774–782
   PubMed Web of Science ®Google Scholar
• Bundred N.J., Chan K., Anderson N.G. Studies of epidermal growth factor receptor inhibition in breast cancer. Endocr. Relat. Cancer 2001; 8: 183–189
   PubMed Web of Science ®Google Scholar
• Moulder S.L., Yakes F.M., Muthuswamy S.K., Bianco R., Simpson J.F., Arteaga C.L. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 2001; 61: 8887–8895
   PubMed Web of Science ®Google Scholar
• Moasser M.M., Basso A., Averbuch S.D., Rosen N. The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001; 61: 7184–7188
   PubMed Web of Science ®Google Scholar
• Ciardiello F., Caputo R., Bianco R., Damiano V., Pomatico G., De Placido S., Bianco A.R., Tortora G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 2000; 6: 2053–2063
   PubMed Web of Science ®Google Scholar
• Sirotnak F.M., Zakowski M.F., Miller V.A., Scher H.I., Kris M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 2000; 6: 4885–4892
   PubMed Web of Science ®Google Scholar
• Moyer J.D., Barbacci E.G., Iwata K.K., Arnold L., Boman B., Cunningham A., DiOrio C., Doty J., Morin M.J., Moyer M.P., Neveu M., Pollack V.A., Pustilnik L.R., Reynolds M.M., Sloan D., Theleman A., Miller P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997; 57: 4838–4848
   PubMed Web of Science ®Google Scholar
• Pollack V.A., Savage D.M., Baker D.A., Tsaparikos K.E., Sloan D.E., Moyer J.D., Barbacci E.G., Pustilnik L.R., Smolarek T.A., Davis J.A., Vaidya M.P., Arnold L.D., Doty J.L., Iwata K.K., Morin M.J. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther. 1999; 291: 739–748
   PubMed Web of Science ®Google Scholar
• Chan K.C., Knox W.F., Gandhi A., Slamon D.J., Potten C.S., Bundred N.J. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. Br. J. Surg. 2001; 88: 412–418
   PubMed Web of Science ®Google Scholar
• Chan K.C., Knox W.F., Gee J.M., Morris J., Nicholson R.I., Potten C.S., Bundred N.J. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res. 2002; 62: 122–128
   PubMed Web of Science ®Google Scholar
• Medina L., Gomez L., Cerna C., Kraker A., Yochmowitz M., Weitman S. Investigation of the effects of the tyrosine kinase (TK) inhibitor CI-1033 (PD0183805) against human tumor specimens taken directly from patients. Proc. Am. Assoc. Cancer Res. 2000; 41: 483, (abs 3078)
   Google Scholar
• Allen L.F., Cerna C., Gomez L., Yochmowitz M., Medina L., Weitman S. Investigation of the effects of CP-358,774 on various human tumor specimens taken directly from patients. Clin. Cancer Res. 2000; 6(Suppl.), (abs 384)
   Google Scholar
• Dent P., Reardon D.B., Park J.S., Bowers G., Logsdon C., Valerie K., Schmidt-Ullrich R. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol. Biol. Cell 1999; 10: 2493–2506
   PubMed Web of Science ®Google Scholar
• Raben, D.; Helfrich, B.; Phistry, M.; Chan, D.; Bunn, P. ZD1839 (‘Iressa’), an EGFR-TKI, potentiates radiation/chemotherapy cytotoxocity in human non-small cell lung cancer cell lines. Poster presented at 11th NCI-EORTC-AACR, Nov 7–10, 2000, Amsterdam, The Netherlands.
   Google Scholar
• Williams K., Telfer B., Stratford I., Wedge S. Combination of ZD1839 (‘Iressa’), an EGFR tyrosine kinase inhibitor, and radiotherapy increases antitumour efficacy in a human colon cancer xenograft model. Proc. Am. Assoc. Cancer Res. 2001; 42, (abs 3840)
   Google Scholar
• Bianco, R.; Bianco, C.; Caputo, R.; Damiano, V.; Bianco, A.R.; Tortora, G.; Ciardiello, F. Selective inhibition of the epidermal growth factor receptor tyrosine kinase (EGFR-TKI) by ZD1839 (‘Iressa’) potentiates the antitumor effects of ionizing radiation. Abstract accepted for American Association of Cancer Research, 2002.
   Google Scholar
• She, Y.; Haimovitz-Friedman, A.; Miller, V.A.; Rusch, V.W.; Kris, M.G.; Sirotnak, F.M. The selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (‘Iressa’) enhances radiation sensitivity of human tumor xenografts in nude mice. Abstract accepted for American Association of Cancer Research, 2002.
   Google Scholar
• Dorssers L.C., Van der F.S., Brinkman A., van Agthoven T., Veldscholte J., Berns E.M., Klijn J.G., Beex L.V., Foekens J.A. Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs 2001; 61: 1721–1733
   PubMed Web of Science ®Google Scholar
• Gee J.M., Hutcheson I.R., Knowlden J.M., Barrow D., Harper M.E., Jones H.E., Wakeling A.E., Nicholson R.I. The EGFR-selective tyrosine kinase inhibitor ZD1839 (‘Iressa’) is an effective inhibitor of tamoxifen-resistant breast cancer growth. Eur. J. Cancer 2001; 37(Suppl.), (abs 969)
   PubMedGoogle Scholar
• McClelland R.A., Barrow D., Madden T.A., Dutkowski C.M., Pamment J., Knowlden J.M., Gee J.M., Nicholson R.I. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 2001; 142: 2776–2788
   PubMed Web of Science ®Google Scholar
• Nicholson R.I., Hutcheson I.R., Harper M.E., Knowlden J.M., Barrow D., McClelland R.A., Jones H.E., Wakeling A.E., Gee J.M. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr. Relat. Cancer 2001; 8: 175–182
   PubMed Web of Science ®Google Scholar
• Nicholson R.I., Harper M.E., Hutcheson I.R., Madden T.A., Barrow D., Knowlden J.M., Jordan N., Wakeling A.E., Gee J.M. ZD1839 (‘Iressa’) improves the antitumour activity of tamoxifen (‘Nolvadex’) in antihormone-responsive breast cancer cells. Clin. Cancer Res. 2001; 7(Suppl.), (abs 557)
   PubMedGoogle Scholar
• Normanno N., Campiglio M., De Luca A., Somenzi G., Maiello M., Ciardiello F., Gianni L., Salomon D.S., Menard S. Cooperative inhibitory effect of ZD1839 (‘Iressa’) in combination with trastuzumab (‘Herceptin’) on human breast cancer cell growth. Ann. Oncol. 2002; 13: 65–72
   PubMed Web of Science ®Google Scholar
• Baselga J. Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing. Ann. Oncol. 2002; 13: 8–9
   PubMed Web of Science ®Google Scholar
• Lenferink A.E., Simpson J.F., Shawver L.K., Coffey R.J., Forbes J.T., Arteaga C.L. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu+MMTV/TGF-alpha bigenic mice. Proc. Natl. Acad. Sci. USA 2000; 97: 9609–9614
   PubMed Web of Science ®Google Scholar
• Ranson M., Hammond L., Ferry D., Kris M., Tullo A., Murray P., Miller V., Averbuch S., Ochs J., Morris C., Feyereislova A., Swaisland H., Rowinsky E. ZD1839 (‘Iressa’), a selective oral EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor), is well tolerated and active in patients with solid malignant tumours: results of a phase I trial. J. Clin. Oncol. 2002, in press
   Web of Science ®Google Scholar
• Negoro S., Nakagawa K., Fukuoka M., Kudoh S., Tamura T., Yoshimura N., Takeda K., Tanigawara Y., Swaisland K. Final results of a phase I intermittent dose-escalation trial of ZD1839 (‘Iressa’) in Japanese patients with various solid tumors. Proc. Am. Soc. Clin. Oncol. 2001; 20: 324a, (abs 1292)
   Google Scholar
• Hidalgo M., Siu L.L., Nemunaitis J., Rizzo J., Hammond L.A., Takimoto C., Eckhardt S.G., Tolcher A., Britten C.D., Denis L., Ferrante K., Von Hoff D.D., Silberman S., Rowinsky E.K. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 2001; 19: 3267–3279
   PubMed Web of Science ®Google Scholar
• Giaccone G., Gonzales-Larriba J., Smit E., van Oosterom A., Martins M., Peters G., van der Vijgh W., Smith R., Fandi A., Averbuch S. ZD1839 (‘Iressa’), an orally-active, selective, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is well tolerated in combination with gemcitabine and cisplatin, in patients with advanced solid tumours: preliminary tolerability, efficacy and pharmacokinetic results. Eur. J. Cancer 2001; 37(Suppl. 6)S30–S31, (abs 102)
   PubMedGoogle Scholar
• Hammond L.A., Figueroa J., Schwartzberg L., Ochoa L., Hidalgo M., Olivo N., Schwartz G., Smith L., Ochs J., Rowinsky E.K. ZD1839 (‘Iressa’), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with 5-fluorouracil and leucovorin, in patients with advanced colorectal cancer. Clin. Cancer Res. 2001; 7(Suppl.), (abs 549)
   Google Scholar
• Miller V., Johnson D., Heelan R., Pizzo B., Perez W., Bass A., Kris M., Ochs J., Averbuch S. A pilot trial demonstrates the safety of ZD1839 (‘Iressa’), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 2001; 20: 326a, (abs 1301)
   Google Scholar
• Arteaga C.L., Baselga J. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: Implications for drug development and practice. Clinical Cancer Research 2003; 9(5)1579–89, (English) Review
   PubMed Web of Science ®Google Scholar
• Giaccone G., Johnson D.H., Manegold C., et al. A phase III clinical trial of ZD1839 ("Iressa") in combination with gemcitabine and cisplatin in chemotherapy-na? "ve patients with advanced non-small cell lung cancer (INTACT-1). Ann Oncol 2000; 13(suppl 5)2
   Google Scholar
• Johnson D.H., Herbst R., Giaccone G., et al. ZD1839 ("Iressa") in combination with paclitaxel and carboplatin in chemotherapy-na? "ve patients with advanced non-small cell lung cancer (NSCLC): Initial results from a phase III trial (INTACT-2). Ann Oncol 2002; 13(suppl 5)127
   PubMedGoogle Scholar